Institutional members access full text with Ovid®

Share this article on:

Vulvovaginal Candidiasis in Postmenopausal Women: The Role of Hormone Replacement Therapy

Fischer, Gayle MBBS, FACD1; Bradford, Jennifer MBBS, FRANZCOG2

Journal of Lower Genital Tract Disease: October 2011 - Volume 15 - Issue 4 - p 263-267
doi: 10.1097/LGT.0b013e3182241f1a
Original Articles

Objective: This study aimed to explore the role of hormone replacement therapy (HRT) in susceptibility to vulvovaginal candidiasis (VVC) in a private vulval disease referral practice.

Methods: Between January 2009 and December 2010, 149 healthy, nondiabetic patients with vulvar conditions were compared for significant differences in vaginal swab result, age, and diagnosis between those using and not using HRT. Detailed clinical data were collected from those with VVC.

Results: The mean ages of the HRT (n = 70) and non-HRT (n = 79) groups were 62.5 and 62.5 years, respectively. Positive cultures for Candida were found in 34 (48.5%) of 70 patients on HRT and in 2 (3%) of 79 subjects not on HRT (p < .001). Culture-positive, clinical VVC was identified in 34 (49%) of 70 patients on HRT and in 1 (1%) of 79 patients not on HRT (p < .001). Candida species (32 Candida albicans and 2 Candida glabrata) were isolated from the 34 VVC patients, and of these, 23 (67%) had a history of recurrent or chronic candidiasis before menopause. All 34 had been previously treated with antifungal therapy without ceasing HRT and had been unresponsive to treatment or had relapse after treatment. In 27 (79%) of 34 patients, HRT was suspended during treatment. Of those who remained on HRT during treatment or resumed it after treatment, prophylactic antifungal treatment was initiated in 15 (44%) to prevent recurrence. All patients responded to the antifungal treatment provided HRT was suspended or prophylactic treatment was used.

Conclusions: Postmenopausal women taking HRT are significantly more prone to develop VVC than women who are not and those with VVC are likely to have been susceptible to it before menopause.

Symptomatic vulvovaginal candidiasis after menopause is a potential adverse effect of estrogen replacement therapy.

1Department of Dermatology, Royal North Shore Hospital, University of Sydney, and 2Department of Obstetrics and Gynaecology, Blacktown Hospital, University of Western Sydney, Sydney, NSW, Australia

Reprint requests to: Gayle Fischer, MBBS, FACD, Royal North Shore Hospital LPO, Box 4028, St Leonard's 2065, NSW, Australia. E-mail:

There were no financial interests in the preparation of this article.

The authors have no conflict of interest to declare.

©2011The American Society for Colposcopy and Cervical Pathology